Skip to main content

Research Repository

Advanced Search

Commander: A randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of Rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary ar

People Involved

Professor Andrew Clark A.L.Clark@hull.ac.uk

Type of Project Project
Project Acronym Commander
Status Project Complete
Funder(s) Janssen Cilag Limited
Value £20,804.00
Project Dates Oct 1, 2015 - May 31, 2018

You might also like

Perspective: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction Jan 1, 2017 - Dec 31, 2019
A clinical trial of LCZ verses valsartan in heart failure patients with preserved ejection fraction. The study uses MRI and PET scans to identify amyloid deposits in the brain and any adverse effects of cognitive function of teh study drug, LCZ696.Read More

Galactic-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction Apr 1, 2017 - Jul 31, 2021
Acronym is derived from : Global approach to lowering adverse cardiac outcomes through improving contractility in heart failure.
A phase III randomised placebo controlled clinical trial sponsored by Amgen Inc of omecamtiv mercabil, a study dru... Read More